Bristol Myers gets regulatory approval for anemia drug Reblozyl, secures FDA label expansion
29 Aug 2023
Priority ReviewDrug Approval
Bristol Myers Squibb has scored another win for its anemia drug Reblozyl, revealing Monday evening the FDA granted the drug its third indication.
The FDA approved the drug as a frontline treatment for adult anemia patients with lower-risk myelodysplastic syndromes (MDS) who may require red blood cell transfusions, and who also had not used erythropoiesis-stimulating agents, or ESAs.
The agency accepted an sNDA for the drug back in May, granting it priority review.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.